DocGo Inc. (NASDAQ:DCGO - Free Report) - Equities research analysts at Northland Capmk upped their Q3 2025 earnings per share (EPS) estimates for shares of DocGo in a report released on Friday, February 28th. Northland Capmk analyst M. Latimore now expects that the company will post earnings of $0.04 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for DocGo's current full-year earnings is $0.25 per share. Northland Capmk also issued estimates for DocGo's FY2025 earnings at $0.13 EPS.
DCGO has been the topic of a number of other reports. Stifel Nicolaus lowered their price objective on DocGo from $6.50 to $5.50 and set a "buy" rating on the stock in a research note on Friday. Deutsche Bank Aktiengesellschaft cut DocGo from a "buy" rating to a "hold" rating and lowered their price objective for the company from $5.00 to $2.85 in a research note on Friday. Finally, Needham & Company LLC lowered their price objective on DocGo from $7.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $4.89.
Get Our Latest Stock Analysis on DocGo
DocGo Stock Performance
Shares of DocGo stock opened at $3.09 on Monday. DocGo has a 52-week low of $2.75 and a 52-week high of $5.68. The stock's 50-day simple moving average is $4.58 and its 200 day simple moving average is $4.02. The stock has a market capitalization of $315.34 million, a P/E ratio of 11.04, a P/E/G ratio of 14.16 and a beta of 1.00.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of DCGO. Harbor Capital Advisors Inc. boosted its stake in DocGo by 144.6% in the third quarter. Harbor Capital Advisors Inc. now owns 968,537 shares of the company's stock worth $3,216,000 after buying an additional 572,522 shares in the last quarter. WCM Investment Management LLC lifted its position in DocGo by 0.6% in the third quarter. WCM Investment Management LLC now owns 2,626,971 shares of the company's stock valued at $8,879,000 after purchasing an additional 15,933 shares during the last quarter. GSA Capital Partners LLP raised its holdings in shares of DocGo by 19.7% during the third quarter. GSA Capital Partners LLP now owns 445,805 shares of the company's stock valued at $1,480,000 after acquiring an additional 73,456 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of DocGo by 100.3% during the third quarter. Victory Capital Management Inc. now owns 51,349 shares of the company's stock valued at $170,000 after acquiring an additional 25,714 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of DocGo during the third quarter valued at approximately $62,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
Insider Buying and Selling at DocGo
In other DocGo news, General Counsel Ely D. Tendler sold 23,088 shares of DocGo stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $4.44, for a total transaction of $102,510.72. Following the completion of the transaction, the general counsel now owns 175,645 shares of the company's stock, valued at $779,863.80. The trade was a 11.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.70% of the company's stock.
DocGo Company Profile
(
Get Free Report)
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DocGo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.
While DocGo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.